Biocryst Pharmaceuticals Inc (BCRX) - News Archive

BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) has recently announced that the Brazilian Health Regulatory Agency (ANVISA) has granted approval for ORLADEYO (berotralstat) to be used as a once-daily oral prophylaxis treat...

Biocryst Pharmaceuticals Inc. recently announced the issuance of inducement grants to three newly-hired employees in the form of stock options and restricted stock units (RSUs), as outlined in their press release on Mar...

BioCryst Presents New Real-world Data Showing Rapid, Substantial and Sustained HAE Attack Rate Reductions After Beginning ORLADEYO (berotralstat) TreatmentRESEARCH TRIANGLE PARK, N.C., Feb. 23, 2024 - In a groundbreakin...

In recent news, BioCryst Pharmaceuticals, Inc. has made significant strides in improving the treatment options available for patients with hereditary angioedema (HAE) and has also unveiled promising developments in its...

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)RESEARCH TRIANGLE PARK, N.C., Feb. 02, 2024 - BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) has recently announced the granting of stock options and...

In a significant stride towards medical breakthroughs, renowned pharmaceutical company BioCryst Pharmaceuticals recently announced its preliminary full-year net revenue for 2023, hitting an impressive milestone of $325...

BioCryst Pharmaceuticals Announces Inducement Grants as Part of Employee Compensation Plans, in Alignment with Nasdaq Listing Rule 5635(c)(4)RESEARCH TRIANGLE PARK, N.C., Jan. 03, 2024 - BioCryst Pharmaceuticals, Inc. (...

HAE is a rare genetic condition characterized by unpredictable and recurrent episodes of severe swelling in various parts of the body. These painful episodes can lead to potentially life-threatening complications if not...

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) recently announced that the compensation committee of the company s board of directors has granted stock options and restricted stock units (RSUs) to 16 newly-hired employee...

BioCryst Pharmaceuticals Receives Regulatory Approval for ORLADEYO in ArgentinaBioCryst Pharmaceuticals, a leading biotechnology company, has recently announced the approval of their drug, ORLADEYO (berotralstat), by th...

BioCryst Pharmaceuticals, Inc. recently held its Research and Development (R&D) Day, where the company unveiled updates on its drug discovery process and highlighted additional therapies from its pipeline. The event too...